BMRN · CUSIP 09061G101
BioMarin Pharmaceutical, Inc.
Reported by 3 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-08-24.
- Managers holding
- 3
- Average portfolio weight
- 0.8%
- Combined reported value
- $1.3B
- Research group
- 79
3 of the 79 superinvestors Shameless Cloning tracks reported BioMarin Pharmaceutical, Inc. (BMRN) in their Q2 2026 13F filings, worth $1.3B combined, at an average 0.8% of their portfolios. The largest positions by portfolio weight belong to Viking Global Investors (1.2%), Torray Funds (0.6%), Dodge & Cox Funds (0.4%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Viking Global InvestorsVIKING GLOBAL INVESTORS LP | 1.2% | $435.8M |
| Torray FundsTorray Investment Partners LLC | 0.6% | $4.4M |
| Dodge & Cox FundsDodge & Cox | 0.4% | $849.4M |